Twist Bioscience Corporation (TWST) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $57.41. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is TWST = $48 (-16% upside).
Valuation: TWST trades at a trailing Price-to-Earnings (P/E) of -39.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.15.
Financials: revenue is $377M, +22.8%/yr average growth. Net income is $78M (loss), growing at +22.3%/yr. Net profit margin is -20.6% (negative). Gross margin is 50.7% (+9.3 pp trend).
Balance sheet: total debt is $137M against $473M equity (Debt-to-Equity (D/E) ratio 0.29, conservative). Current ratio is 3.64 (strong liquidity). Debt-to-assets is 21.4%. Total assets: $642M.
Analyst outlook: 10 / 13 analysts rate TWST as buy (77%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 55/100 (Partial), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 70/100 (Pass), Future 49/100 (Partial), Income 10/100 (Fail).
